Cogent Biosciences reported a Phase 3 victory for bezuclastinib in imatinib‑resistant gastrointestinal stromal tumors, halving the risk of progression or death versus sunitinib in the PEAK study and prompting plans for an NDA submission in the first half of 2026. The company also confirmed a second registrational pathway for non‑advanced systemic mastocytosis, pushing two potential NDA filings into view. Investors drove Cogent’s shares sharply higher following the readouts.